Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 8/20 | 0.52 |
| ▸ | STK17B | O94768 | 6/20 | 0.52 |
| ▸ | AXL | P30530 | 3/20 | 0.51 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448511 | 0.95 | STK17A (0.55) | STK17ASTK17BAXLTBK1MAP3K8 | |
| SCHEMBL3449683 | 0.90 | AXL (0.62) | STK17ASTK17BAXLTBK1EGFR | |
| SCHEMBL3447547 | 0.87 | EGFR (0.58) | STK17ASTK17BAXLEGFRMAP3K8 | |
| SCHEMBL13310830 | 0.85 | AXL (0.49) | STK17ASTK17BAXLEGFRMAP3K8 | |
| SCHEMBL13310343 | 0.84 | STK17A (0.52) | STK17ASTK17BAXLTBK1PDPK1 | |
| SCHEMBL3449758 | 0.82 | STK17A (0.56) | STK17ASTK17BAXLTBK1EGFR | |
| SCHEMBL3450813 | 0.81 | AXL (0.46) | STK17ASTK17BAXLEGFR | |
| SCHEMBL13310831 | 0.81 | STK17A (0.51) | STK17ASTK17BAXLEGFRMAP3K8 | |
| SCHEMBL3448855 | 0.79 | STK17A (0.62) | STK17ASTK17BAXL | |
| SCHEMBL3449465 | 0.79 | STK17A (0.55) | STK17ASTK17BAXLTBK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| WO-2010038081-A2 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | STK17A 1984/4885STK17B 2457/4885AXL 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.